NASDAQ NMS - GLOBAL MARKET · OCGN

-0.88% · -$0.0115 · Vol 6.3M

After hours · updated 16:52:50 ET

Ocugen Inc

Biotechnology

$1.30

Card

Relationship Map

Veridion Score

BETALOW CONF · 5/6 factors

Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET · OCGN

Methodology

OCGN

Ocugen Inc

Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET

23/100

AVOID

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

23/ 100

Veridion Score

AVOID · LOW confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: LOW · 5/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is OCGN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move OCGN next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 4
Score
Score moved +5
18/AVOID -> 23/AVOID
Veridion score historySource
Nov 8
CongressChecking access
Christopher L. Jacobs sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 16
CongressChecking access
Christopher L. Jacobs purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Ocugen Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

2014

Employees

116

Country

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$1.30

Day high

$1.33

Day low

$1.27

Previous close

$1.31

52W high